Advertisement

Risk factors and current management of venous thromboembolism in patients with primary immune thrombocytopenic purpura.

Published:February 07, 2021DOI:https://doi.org/10.1016/j.ejim.2021.01.026
      immune thrombocytopenic purpura (ITP) is a rare hematologic disorder characterized by isolated thrombocytopenia due to platelet destruction, without abnormalities of erythrocyte or leukocyte number or morphology. The incidence ranges between 1.6 to 3.9 per 100.000 patient-years, with higher rates among the elderly [
      • Neunert C
      • Terrell DR
      • Arnold DM
      • et al.
      American Society of Hematology 2019 guidelines for immune thrombocytopenia.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Neunert C
        • Terrell DR
        • Arnold DM
        • et al.
        American Society of Hematology 2019 guidelines for immune thrombocytopenia.
        Blood Adv. 2019; 3 ([published correction appears in Blood Adv. 2020 Jan 28;4(2):252]): 3829-3866https://doi.org/10.1182/bloodadvances.2019000966
        • Neunert C
        • Noroozi N
        • Norman G
        • Buchanan GR
        • Goy J
        • Nazi I
        • Kelton JG
        • Arnold DM.
        Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review.
        J ThrombHaemost. Mar 2015; 13 (Epub 2015 Jan 14. PMID: 25495497; PMCID: PMC4991942): 457-464https://doi.org/10.1111/jth.12813
        • Fontana V
        • Jy W
        • Ahn ER
        • Dudkiewicz P
        • Horstman LL
        • et al.
        Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP.
        Thromb Res. 2008; 122: 599-603
        • Shulman S
        • Kearon C
        on behalf the subcommittee on control of anti- coagulation on the Scientific and Standardization committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations and antihemostatic medicinal products in non-surgical patients.
        J ThrombHaemost. 2005; 3: 692-694
        • Lee DH
        • Barmparas G
        • Fierro N
        • et al.
        Splenectomy is associated with a higher risk for venous thromboembolism: A prospective cohort study.
        Int J Surg. 2015; 24: 27-32https://doi.org/10.1016/j.ijsu.2015.10.011
        • Ghanima W
        • Cooper N
        • Rodeghiero F
        • Goudeau B
        • Bussel JB.
        Thrombopoietin Receptor Agonists: Ten Years Later.
        Haematologica. June 2019; 104: 1112-1123
      1. Leader A, Ten Cate V, Ten Cate-Hoek AJ, Beckers EAM, Spectre G, Giaccherini C, Gurevich-Shapiro A, Krashin E, Raanani P, Schouten HC, Falanga A, Ten Cate H. Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment. Eur J Intern Med. 2020 Jul;77:86-96. doi: 10.1016/j.ejim.2020.03.005. Epub 2020 Mar 13. PMID: 32173172.